Drugs / ITI-1284
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06786286 | Jan → Mar 2025 | — | Intra-Cellular Therapies, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06299410 | Apr 2024 → Jul 2026 overdue | — | Intra-Cellular Therapies, Inc. | Recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06701903 | Nov 2024 → Jun 2027 expected | generalized anxiety disorder | Intra-Cellular Therapies, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06651567 | Oct 2024 → Dec 2027 expected | — | Intra-Cellular Therapies, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06540833 | Aug 2024 → Sep 2028 expected | psychotic disorder | Intra-Cellular Therapies, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06480383 | Aug 2024 → Jun 2027 expected | generalized anxiety disorder | Intra-Cellular Therapies, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ITI-1284 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06651567 ↗ |
| Route | Other | “ITI-1284 10 mg tablet, taken once daily, sublingual administration.” NCT06480383 ↗ |